GlaxoSmithKline CEO Andrew Witty attributes the company's success to sticking to the tried-and-true business model of investing in research and development and not transitioning to an acquisition model.
Witty told CNBC's "Closing Bell" on Monday that the key is to be patient and to see the value of investing in innovation.
"What we have to stay focused on is the fundamentals of the value of innovation and discovery of medicines and vaccines that make a real difference to patients," he said.
"We've been criticized by people at times for not being exciting enough in terms of embracing the new ideas of how to quickly move things forward. I think the reality of what we've seen is there aren't any shortcuts," Witty said.